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ABSTRACT 
Cancer research is an essential part of national cancer control programmes and the 
emerging economies of Central and Eastern Europe (CEE) and Russian Federation-Central 
Asia (R-CA) (Commonwealth of Independent States) remain relatively under-studied.  Here, 
we map cancer research activity from the 29 countries across these regions over a ten-year 
period (2007-16), using a standard scientometric approach.  Research activity was compared 
with the countries’ wealth, and with the disease burden from different cancers, and 
analyses were also performed by research domain (e.g., fundamental cancer biology, 
surgery).  We found that although there was a correlation between outputs and national 
wealth, there were many outliers, the CEE countries publishing relatively more, and the R-
CA less.  Outputs reflected cancer burdens but there was a relative paucity of research on 
lung, colorectal, and gastric as well as pancreatic cancer, as well as research domains such 
as screening and palliative care.  Clinical trials accounted for only 3% of all research outputs 
from all countries, and were very international, with on average 1.5 CEE countries and 8.0 
others involved in each paper, and they were heavily cited (on average, 84 times in five 
years).  Poland was by far the most research active country, but significant needs and 
opportunities have been identified to expand cancer research activity in all CEE and R-CA 
countries to enhance national cancer control planning.  
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INTRODUCTION 
Mapping research activity is critical for evidenced-based policy and the development of 
national cancer control plans 1. In this analysis, we focus on Central and Eastern Europe 
(CEE), Russia and Central Asia (R-CA) (Table 1) as their socio-political and science and 
technology trajectories as well as unmet needs have been very different from those 
experienced by higher income European countries2. Countries that form part of these 
unique regions have substantially different burdens of cancer, as a proportion of total NCD 
(Figure 2) as well as different levels of development which require unique policy responses 
in terms of planning and research systems development3. While cancer mortality in Europe 
has declined steadily 1–4, this trend is not seen in CEE and R-CA where some countries even 
experienced an increase in cancer mortality2,4. This discrepancy has complex background, 
probably with unequal effects in different countries4,5. Causes may include differences in 
distribution of risk factors, less primary and secondary prevention and consequently higher 
cancer stage diagnosis, more deadly cancer types, lower access to quality care, fewer 
available treatment options with lower availability of inovative drugs, shortage of 
radiotherapy and other equipment, lack of national cancer plans, lack of multidisciplinary 
teams, absence of comprehensive cancer registries and, as focus of this article, lack of 
cancer research. 5–7 To date, most of research intelligence and mapping for cancer control 
has focused on high income countries, and there is a paucity of high resolution comparative 
data to inform policy-makers at both national and supra-national levels in many emerging 
powers6. Our quantitative analysis builds and expands (geographically) on the detailed and 
careful ‘current situation analysis’ performed by Vrdoljiak and colleagues in 2016 on the 
state of cancer control and care in CEE and a recent pan European mapping analysis7. In 
light of the rapidly increasing cancer burden across these regions, as well as the need for all 
these countries to deliver on the ambitious non communicable disease targets for Universal 
Health Coverage and the Sustainable Development Goals, there is a clear need for more 
cancer research intelligence to inform policy-makers. Here, we apply well validated 
scientometric tools to understand the state of cancer research across Central and Eastern 
Europe, Russia and Central Asia over the last ten years8,9. 
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METHODOLOGY 
Articles and reviews from 29 countries in CEE and R-CA (Table 1) were identified in the Web 
of Science (WoS) for the Science Citation Index Expanded and the Proceedings for the 10 
calendar years, 2007-16, by means of a complex cancer filter as previously described10. This 
is the most comprehensive global index of cancer publications, however, this does not 
include non-Indexed country language specific papers.  This consisted of lists of 185 
specialist cancer journals and 323 title words or phrases with a precision (p, specificity) of 
0.95 and a recall (r, sensitivity) of 0.98.  The ratio of these two gave its calibration factor = 
p/r = 0.97.  Full bibliographic details of these papers were downloaded to a series of files 
and converted to an MS Excel spreadsheet by means of a special VBA program 
(Evaluametrics Ltd). 
In order to evaluate the cancer research papers in context, the numbers of biomedical 
research papers from the countries were also determined for the same years, by means of 
another complex filter, previously described11.  
The addresses displayed in each of the country’s cancer research papers were parsed by a 
special VBA program to show the fractional contributions of each country to each paper, 
and also their integer contributions (for example, a paper with two Polish(PL) and three 
Russian(RU) addresses would be scored 0.4 for PL and 0.6 for RU on a fractional count basis, 
but 1 each on an integer count basis).  The growth rate (annual average percentage growth, 
AAPG) was only shown for half of the 29 countries (for the others, there was no clear trend 
with time) on a fractional count basis from a plot of output against time and the best-fit 
(least squares) exponential trend-line.  Country contributions over the decade were also 
plotted against each country's wealth, as measured by its Gross Domestic Product (GDP), 
which shows whether countries are publishing more or less than expected from the ratio for 
other countries in the geopolitical group.  They were also plotted against population size, 
but the correlation is normally much weaker, as was the case here, so the results are not 
shown.  We compared the percentage of each country's overall biomedical research output 
that cancer research represented in the 2007-16-time period, against the percentage of its 
total disease burden in DALYs (WHO, 2012) that was due to cancer. 
International collaboration is often seen as an important indicator of a country's wider 
research engagement and a marker of higher impact.  This was determined as the 
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percentage of each of the 29 countries' integer count output from within its borders (its 
fractional count), from other members of CEE and R-CA, and from the rest of the world.  A 
distinction was made between the 11 CEE countries that were EU Member States, those 
that were CIS members (or associates) and the 6 Balkan countries, in order to see if EU 
membership had made a difference to collaborative patterns, and data were obtained and 
compared for two quinquennia, 2007-11 and 2012-16, so as to reveal whether these 
patterns (in cancer research output) were changing, within each of the three groups. 
Two further VBA programs were applied to the database of all papers over this period to 
evaluate the distribution of cancer papers for 23 different anatomical sites, and in 12 
different research domains.  These are listed in Table2 and the codes for each anatomical 
site or research domain are indicated in the Figures and Tables.  These "sub-filters" were 
based on title words and journal name strings.   
Another important aspect of cancer research is the publication of the results of clinical trials.  
Many of these trials are multi-national and the participation of local researchers is often 
important for the approval of new drugs, or other medical procedures (e.g. innovative 
surgical or radiotherapy interventions) in particular countries.  We searched for clinical trial 
activity with the following phrases in the titles of the papers: “phase 1/2/3*stud/trial”, 
“phase I*stud/trial”, “randomis/zed study/trial”,  "clinical/controlled trial". Clinical trial 
activity was further classified by the research domain: drugs (chemotherapy or targeted 
therapy), surgery or radiotherapy, and by the cancer site. 
We also determined the impact of the cancer research papers by means of citation counts in 
the WoS.  We used a standard citation window of five years, beginning with the year of 
publication of each paper, as a compromise between immediacy and the need to cover the 
peak year (usually two or three years after the publication year).  Thus, we determined the 
citation counts in the WoS for each country’s papers from 2007-12 (six years).  Because they 
are not distributed normally, we chose three indicators to best capture accurate citation 
counts, namely arithmetic mean (called actual citation impact, ACI), geometric mean (GCI), 
and numbers in the top centiles for a group (top 1%, top 2% and top 5%)12.  The latter are 
presented as "world-scale" values which are 100 times the ratio of the actual percentage of 
papers in a given centile to the nominal value13.Because many papers have zero cites, we 
add unity to each citation count, determine their geometric mean, and then subtract unity 
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from the result.  This is performed by taking the arithmetic mean of the logarithm of the 
citation counts.  This geometric mean is less influenced by the presence of a few very highly 
cited papers than is the arithmetic mean. All these indicators were determined on the basis 
of fractional country counts, in order to ensure accuracy, as to attribute the many citations 
that a multi-national paper may have received to each of the participating countries, some 
of which may have only made a small contribution, would, we reason, not represent the 
actual situation.   
Mean ACI, GCI and WS values were also determined for the various cancer anatomical site 
and research domain papers, and for clinical trial papers, but on an integer count basis, as 
these attributions were not fractionated.  The intention was to show whether some types of 
cancer research attracted more citations than others.  
Because of Russia’s dominance both in terms of wealth and population, we also made a 
specific study of two aspects of cancer research in that country.  The first to understand the 
changes in volumes over a much longer time period (1977-2016) and the gender ratio 
between researchers in these outputs.  The methodological approach has been described in 
detail elsewhere14.  The second aspect for specific study was the presence of cancer 
researchers with one or more of 2400 Russian names (ending in “-enko”, “-ev”, “-nin”, and 
“-ov” and their feminine equivalents) on non-Russian origin papers, to study migration 
patterns, as previously described15.  
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RESULTS 
The numbers of cancer papers, on both integer and fractional counts, for the 29 CEE and R-
CA countries are shown in Table 3.  The integer counts are compared with the countries' 
biomedical research outputs to give the fraction of the latter that is specifically related 
tocancer; the fractional counts are used to show the annual average percentage growth, but 
only for the leading 15 countries, as the annual outputs for the remaining countries were 
extremely variable, making it very difficult to assign a meaningful growth rate (e-Figure 1, e-
Figure 2).  The growth rate is highest in the three Baltic states (Estonia, Latvia, Lithuania) 
and in Romania.  It is very low in Bulgaria and Belarus, and actually negative in Croatia (HR).  
It is interesting to see that the growth is not equcal in all EU Member States, while more or 
less all Balkan and CA countries, except Serbia and Russia, are lagging behind.  Cancer 
research activity, as a fraction of all biomedical research, varies between zero in 
Turkmenistan and around 14% in Latvia.  
Research outputs tended to correlate better with GDP rather than with population size 
(Figure 3).  The correlation, however, is only moderate (r = 0.743), but it does show that 
there is a huge variation in the volume of cancer research papers compared with national 
wealth.  (When output is plotted against population size, the correlation with the least-
squares power law line is much poorer, r = 0.37.)  The CEE all publish more cancer research 
papers than expected, as does Serbia (RS).  For example, Serbia publishes more than 240 
times as much as Uzbekistan (UZ), although the latter country has a higher GDP.   
International collaboration has been increasing steadily over the decade. The amount of 
international collaboration varied by country; Figure 4 shows the results based on fractional 
counts.  EU members (blue bars) tend to collaborate more with countries from RoW (yellow 
bars).  For most of the CEE countries, international collaboration has increased in the period 
between 2012-16 when compared to 2007-11, see e-Figure 5, especially in Bosnia & 
Herzegovina (BA). 
Figure 6 shows the correlation between the overall burden from different cancers across all 
countries (except for Kosovo for which there are no data) and the amount of research that 
these countries perform on a fractional count basis, expressed as a percentage of all cancer.  
Belarus is the only country where cancer research exceeds the amount that would be 
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proportional to the cancer disease burden; most other countries only publish of the order of 
half this amount (dashed line), and Armenia (AM) and Estonia (EE) much less than this. 
e-Figure 7 compares the amount of cancer research conducted on each of the main cancer 
anatomical sites, see Table 2, with the percentage of their burden compared with that from 
all cancers.  Malignant melanoma (MEL), cancers of the central nervous system (CNS) and 
blood cancers (HAE) dominate relative to other cancers, whereas pancreatic (PAN), gastric 
(STO) and oesophageal cancers (not shown, values are 2.32, 0.64) are under-represented by 
a factor of at least two, and for lung cancer (LUN, a major burden in both CEE and R-CA 
countries) by a factor of more than four. 
The research portfolio is dominated by cancer biology (particularly genetics) with over 22% 
of the total, and pharmaceuticals (chemotherapy plus targeted therapy, 10.5%) (Figure 8).  
There is also a paucity of research on screening and on palliative care.  Clinical trials papers 
numbered 944 in total, and increased slightly from 2.4% of the total in 2007-09 to 3.0% in 
2014-16.  Almost two thirds of the papers were on drugs (624; 66%).  There were relatively 
few on radiotherapy (82; 8.7%) or on surgery (70; 7.4%).  Three cancer sites dominated 
clinical trials: breast (164 papers, 17.4%), lung (158; 16.7%) and blood (145; 15.4%). 
Citation scores for CEE and R-CA cancer papers are presented in Table 4 according to the 
three measures: arithmetic mean (ACI), geometric mean (GCI) and World-Scale (WS) at 
three centiles: 1% (164 cites in 5 years), 2% (93 cites) and 5% (47 cites).  No country 
achieved an ACI value equal to or above the mean for the whole group (14.3 cites) on a 
fractional count basis. The mean ACI values for papers for each cancer site are shown in e-
Figure 9, and for each research domain (including clinical trials) in e-Figure 10.  Papers on 
kidney cancer are the most cited, although they represented only 3% of those with citation 
scores, as are papers on targeted chemotherapy and ones on clinical trials.  These latter 
papers were very international, with on average 17.0 and 9.6 countries represented 
respectively. 
Because of its economic dominance, we investigated specific aspects of cancer research in 
the Russian Federation.  In 2009-13, overall there were 128 papers concerning clinical trials, 
and the Russian contribution was 23.4 papers on a fractional count basis.  A majority of the 
papers (n=123, or 96%) acknowledged specific funding, almost all from commercial sources. 
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We also investigated the location of cancer researchers with Russian surnames.  We 
selected over 2400 Russian names and looked at their research activity (either within Russia 
or in other countries), e-Figure 11 .  The top graph shows a gradual rise in output until 1990, 
and then a precipitous decline, especially research activity involving men (suggesting a 
significant migration or cessation of this group), and then a gradual increase, accelerating 
after 2005 to levels higher than before the end of the USSR.  The bottom graph indicates 
that there were far more male Russian scientists than females conducting cancer research in 
other countries: the totals include those who were already present in other countries, so 
clearly there was a major exodus of male Russian scientists particularly after the mid-1990s, 
and one that continued to accelerate.  There were far fewer cancer papers with female 
Russian scientist names in this period, suggesting that they tended to stay in Russia rather 
than go abroad. 
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DISCUSSION 
There is significant evidence that in order to improve cancer outcomes, countries need to 
build their research capacity16. Not only does this lead to better patient outcomes through 
better general cancer knowledge and more rigorous quality and adherence to clinical 
guidelines, but it also provides evidence to inform national cancer control planning. The 
countries in our analysis situated in Central and Eastern Europe and Central Asia all have 
unique and complex historical, political, economic and health trajectories. Furthermore, 
their therapeutic geographies are complicated, with significant inequalities, refugees, ethnic 
minorities, migration patterns, and rurality, and their relative dimensions of socio-
development are uneven, from Russia at a population of over 143M `and a GDP of 3.6 
trillion USD to Montenegro at around 1M population and a GDP of  around 8 billion. These  
regions are all experiencing increasing cancer burden as they move through their respective 
demographic, epidemiological and development transitions17.  
Despite issues around the completeness of the registration of cancer cases, it is clear that 
increasing prosperity (GDP/capita) for the countries in our study is aligned with increasing 
cancer burden. For both CEE and CIS countries, the importance of prevention and public 
health for reducing such trajectories is crucial. However, our analysis shows that these are 
among the most poorly researched areas across all research domains. More in-depth cancer 
site-specific analysis shows remarkable similarities between the countries with lung, colon, 
rectal, breast and gastric dominating the cancer landscape.  Taken together, haemato-
oncological cancers also pose a significant burden.  The high burden of colorectal, and 
gastric (particularly in CIS countries) again points to the importance of public health e.g. 
(eradication of H pylori for gastric cancer) and screening (coupled with efficient multi-modal 
treatment) for colo-rectal cancer.  However, both public health and screening are orphan 
areas of research across all countries. Furthermore, considering the burden of colorectal, 
lung and gastric cancer, the research dedicated to these site-specific malignancies falls 
seriously short of what is required.  It must be noted that both in CEE and CIS countries, 
evidence-based health policies are the exception rather than the rule. Generally, medical 
(and general science) research priorities are not determined by the local or national needs, 
but imposed by the European or international financing organizations. There is also 
significant focus in research on both cancer biology discovery, as well as research on cancer 
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drugs (which includes biomarker, chemotherapy and targeted therapy); biomarker and 
chemotherapy outputs when added to the former make up nearly 40% of total domain-
specific research activities.  Palliative care, screening and radiation oncology all are 
significantly below the percentages we see in other comparable EU countries.  However, it is 
clear that international clinical trials, particularly those involving new molecular targeted 
therapies dominate the research landscape (20% of overall research outputs across CEE and 
R-CA).  These findings reinforce the need for more properly designed, country-or-region 
specific studies, with socio-economic models to help inform prioritisation of therapeutic 
interventions, help manage introduction of new technologies (medicines, surgery, 
radiotherapy) and deliver affordable and equitable care and better outcomes. The lack of 
epidemiological research is also in a large part due to the lack of high quality cancer 
registries5,18, a key policy recommendation from previous analysis19. It is also clear from this 
previous policy analysis that if many of the recommendations for improving care are to be 
realised both in CEE and R-CA (e.g. screening programs, development of clinical guidelines, 
pharmacoeconomic evaluations, allocative efficacy for cancer budgets, and nationwide 
prevention programmes) then (sub)region-specific data is going to be required, and this can 
only be achieved  through significant enhancement of research activities in these domains, 
which would also drive more affordable innovation in cancer20.   
Many CEE have performed well in delivering research outputs commensurate or above what 
would be expected for their respective wealth, especially Poland. CIS countries, however, 
have fallen behind, especially Kazakhstan and Russia. However, despite the significant 
research activity of Poland, it’s international impact (measure by world scale values) 
remains modest with Czech Republic and Hungary performing better. This phenomenon is 
particularly striking for those CEE countries with a high annual publication growth rate (the 
Baltic states and Romania) but a limited international impact. One possible explanation is 
the nature and impact of national legislations with regards to academic advancement. For 
example, in Romania it is mandatory to have a certain number of scientific publications in 
order to get an academic promotion but the quality and thei impact factor of these journals 
are not leading criteria.Furthermore, despite significant bilateral Science and Technology 
(S&T) agreements between CEE and Central Asian CIS countries, this has not translated into 
joint cancer research programmes. Our analysis suggests that a number of countries in CEE 
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and, in the future, R-CA could and should be leading more international cancer studies and 
trials21.The growing internationalisation of cancer research from Central Asia is, in part, due 
to wider, often generic co-operation and partnership agreements, such as the 719 million 
euro Development Co-operation Agreement (from 2007 to 2013). Our analysis has also 
identified other anomalous areas that warrant further country-specific investigation. 
Kazakhstan for example, with an R&D expenditure as a % of GDP of nearly 0.2%, but with 
424 self-declared research organisations with over 17,000 personnel, clearly has significant 
potential to rapidly increase its cancer research activities.  
International collaboration is remarkably heterogeneous. However, two crucial trends come 
out of our analysis. The first is that Russia as well as other CA countries remains relatively 
introspective, with most research conducted within national borders. Despite this, Russian 
cancer researchers have retained an impressive impact, with a world scale value rivalled 
only by the Czech Republic (Ukraine is a major outlier because of size). The second trend we 
have uncovered is that CEE countries broadly direct their international collaborations 
towards the EU, a trend that has almost certainly been driven by EU Framework research 
funding programmes, thus showing the impact of a pan-European research funding policy. 
The overall trend across all countries is a moderate increase in internationally collaborative 
research activities. In no case has a country gone backwards. The importance of 
internationalisation in Research and Development has been hypothesised for some time,22 
but it has only become apparent relatively recently how crucial internationalisation can be 
for research systems development and the current study adds to this body of evidence . 
Internationalisation in R&D drives quality and excellence, market share, cost optimisation 
and wider science diplomacy. Our analysis shows that CEE countries that were part of the 
EU benefited from European Commission programmes, starting with 4th Framework 
Program (FP) with utilisation of the two main schemes for stimulating research between CEE 
and the wider EU – PECO and COPERNICUS. However, from a cancer research perspective, 
we found little impact of the collaboration programmes set up in the mid 1990’s to engage 
wider Central Asia e.g. International Association for Cooperation with Scientists from the 
former Soviet Union (INTAS). This may have been in part due to the premature ending of 
this programme in early 2000, with the policy re-orientation of the EU in FP6 and 7, and a 
lack of success of Central Asian partners in winning programmatic funding23. The Russian 
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Federation, however, did have the highest rate of participation as a ‘third country’ up to and 
including the EU’s Framework 7 programming. Yet, this seems to have had only a modest 
impact in the cancer research domain.  
Our in-depth analysis of Russian Federation cancer researchers found that the gender gap 
that developed in the 1980’s between male and female researchers did close, although 
there were indications that this was starting to widen once more as outputs grew from the 
mid 2000’s. More worryingly for Russian cancer research, there was significant numbers of 
Russian researchers appearing on cancer research outputs from other countries, a trend 
that has been, and continues, to grow since the late 1980’s, irrespective of international 
engagement, and bilateral international collaboration agreements around discovery science 
. At present, the Russian Federation is undergoing significant changes in the fight against 
cancer. At the national level, a national strategy for combating cancer is being developed, it 
should be submitted by the Russian government in 2018. A network of national medical 
centers for the research and treatment of cancer, including of pediatric cancer, has been 
implemented since 2016, a program of government support for independent research in the 
field of oncology. 
In developing their cancer research systems, it is clear that many of the low and lower 
middle-income countries from this group e.g. Uzbekistan and Tajikistan, do not have the 
fiscal headroom at present to establish effective cancer research programmes. Instead, the 
priorities for these countries must be to build basic health systems as well as some form of 
science and technology base. More broadly, the regional development priorities have been 
economic and industrial, and not health or research, particularly in Central Asia. There are 
clearly opportunities for more regional co-operation in both general and cancer-specific 
research, building on the Eurasian Economic Commission and the Economic Cooperation 
Organisation. Technical co-operation in science (amongst other areas) is already part of the 
United Nations Industrial Development Organisation mandate, and this almost doubled 
since 201224. However, an analysis of expenditure reveals the majority of resources being 
earmarked for energy, poverty reduction, and trade capacity building. There is clearly an 
urgent need to revisit this to accelerate not only cancer but overall NCD control25. Platforms 
already exist, and could be utilised for cancer research, for regional and global outreach, 
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and high-level missions between and outside CEE and R-CA, focusing on cancer and NCD 
research capacity building could pay dividends. For example, over the last 5 years the US-
Polish Cancer Research group have provided a platform for cancer planning for care and 
research with international partners. A strategy of ‘cancer research inclusion’ by the EU and 
USA, for example by funding research partnerships between major cancer centres26, could 
also help bridge and develop relationships for wider research system reforms, building on 
existing institutional partnerships within and outside the regions27.  
Finally, it is clear from empirical work around expenditures and mortality-incidence ratios 
that country specific funding for public sector cancer control, including cancer research, is 
too low (even for the stage of development for each country)28. These deficits cannot be 
‘made up’ from external collaborations or resources29, neither can they be expected to 
‘trickle down’ from general S&T funding or substituted by the private sector. There is a 
critical need to find the fiscal headroom to support our policy recommendations for funding 
cancer research of public value,30which will have significant national and international 
impact31.   
Policy Recommendations for Cancer Research Systems (Pull out box in main text) 
1. Adjust and / or implement national cancer research policy strategies as part of wider 
National Cancer Control Plan reforms.  
2. Strengthen human resources for cancer research, particularly in clinical research, 
and in domains such as surgery and palliative care 
3. Strengthen therole of public sector funding both nationally, and through 
collaborations, internationally. Create within this framework, clear national cancer 
research policy needs for engagement with the private sector 
4. Build better (sub)regional co-operation, both in cancer research capacity and 
capability training and in the creation of more resources for research teams 
5. Establishment of national cancer medical centers for the research and treatment 
integrated into a joint network. 
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Table 1.  List of CEE (Central &Eastern European) countries, with ISO2 codes; group (BALK = 
Balkan countries, CIS = Members or associates of Commonwealth of Independent States, EU 
= European Union Member States); Gross Domestic Product in 2011 (USD, billion); and 
population in 2009, million. 
Country ISO2 Group GDP Pop'n Country ISO2 Group GDP Pop'n 
Albania AL BALK 12.8 3.6 Lithuania LT EU 42.7 3.6 
Armenia AM CIS 10.1 3.0 Montenegro ME BALK 4.5 0.7 
Azerbaijan AZ CIS 62.3 8.2 Poland PL EU 514 38.5 
Belarus BY CIS 55.5 9.6 Moldova MD CIS 7.0 4.3 
Bosnia &Herz. BA BALK 18.0 4.6 Romania RO EU 190 22.2 
Bulgaria BG EU 53.5 7.2 Russia RU CIS 1850 140 
Croatia HR EU 63.8 4.5 Serbia RS BALK 45.1 7.4 
Czech Republic CZ EU 215 10.2 Slovakia SK EU 96.1 5.5 
Estonia EE EU 22.2 1.3 Slovenia SI EU 49.6 2.0 
Georgia GE CIS 14.3 4.6 Tajikistan TJ CIS 6.5 7.3 
Hungary HU EU 140 9.9 Macedonia MK BALK 10.3 2.1 
Kazakhstan KZ CIS 178 15.4 Turkmenistan TM CIS 25.7 4.9 
Kosovo XK BALK 6.5 1.8 Ukraine UA CIS 165 45.7 
Kyrgyzstan KG CIS 5.9 5.4 Uzbekistan UZ CIS 45.4 27.6 
Latvia LV EU 28.3 2.2           
 
  
Table 2.  List of sites to which cancer research papers could be assigned, with trigraph codes, 
and of domains, with tetragraph codes. 
Manifestation Code Manifestation Code  Research domain Code 
Bladder BLA Breast MAM  Cytotoxic CXT CHEM 
Bone BON Melanoma/skin MEL  Diagnosis DIAG 
Cervix CER Oesophagus OES  Epidemiology EPID 
Central nervous system CNS Ovaries OVA  Cancer Biology GENE 
Colon / Rectum COL Pancreas PAN  Palliative Care PALL 
Gallbladder GAL Prostate PRO  Pathology PATH 
Haematological HAE Stomach STO  Prognosis PROG 
Head & Neck/Mouth HEN Testicles TES  Quality of Life QUAL 
Kidney KID Thyroid THY  Radiotherapy RADI 
Liver LIV Uterus UTE  Screening SCRE 
Lung, Trachea, Bronchus LUN Vulva VUL  Surgery SURG 
Lymphoma LYM    Targeted therapy TARG 
 
  
Table 3.  Outputs of biomedical (BIOM) and oncology (ONCOL) research papers, 2007-16, from 
29 CEE/CIS RF countries (for codes, see Table 1), with percentage of biomedical research on 
cancer, and annual average percentage growth (AAPG) for the leading 15 countries. 
ISO2 BIOM ONCOL % BM AAPG 
 
ISO2 BIOM ONCOL % BM 
 
INT INT FRAC INT FRAC 
  
INT INT FRAC INT 
PL 91612 11585 8860 12.6 6.7 
 
BA 2118 243 137 11.5 
CZ 44671 5352 3421 12.0 5.5 
 
KZ 1099 98.0 50.9 8.9 
RU 55620 4077 2744 7.3 7.5 
 
MK 1289 95.0 62.7 7.4 
HU 29324 3085 1910 10.5 5.1 
 
AM 1687 73.0 45.9 4.3 
RO 22833 2875 2116 12.6 15.0 
 
GE 1594 61.0 27.7 3.8 
RS 18323 2299 1853 12.5 7.0 
 
AL 589 45.0 23.3 7.6 
SI 13788 1546 1003 11.2 4.7 
 
ME 509 43.0 22.2 8.4 
HR 14760 1481 1115 10.0 -0.9 
 
MD 518 39.0 18.6 7.5 
SK 12166 1304 803 10.7 5.6 
 
UZ 527 22.0 7.56 4.2 
BG 8979 776 512 8.6 0.6 
 
AZ 481 18.0 6.45 3.7 
UA 7587 637 298 8.4 8.6 
 
KG 267 14.0 4.91 5.2 
LT 6324 575 393 9.1 14.0 
 
XK 100 5.00 3.17 5.0 
BY 2223 255 98.8 11.5 2.6 
 
TJ 100 2.00 0.71 2.0 
LV 1848 255 113 13.8 15.2 
 
TM 9 0 0 0.0 
EE 5646 253 111 4.5 13.1 
 
EEU 324937 33641 25762 10.4 
 
  
Table 4.  Mean five-year citation scores (ACI, arithmetic mean, and GCI, geometric mean) for 
16 leading CEE/CIS countries (with at least 90 citable papers), and numbers in top centiles and 
mean world-scale value; all based on fractional counts of countries.  Countries ranked by 
mean world-scale value.  ISO country codes in Table 1 . 
  ACI GCI top1% top 2% top 5% WS 1% WS 2% WS 5% Mean WS 
Cites:     164 93 47         
UA 13.2 3.5 1.6 3.5 6.8 107 119 92 106.0 
RU 7.7 2.3 5.4 10.8 30.1 40 40 44 41.4 
CZ 11.4 6.0 4.8 13.3 55.2 26 36 60 40.6 
HU 10.3 5.2 2.0 6.9 22.7 20 34 45 33.1 
EE 10.8 6.0 0.2 0.2 1.0 35 17 42 31.2 
PL 8.0 3.5 10.7 21.6 77.7 23 23 34 26.8 
SI 8.7 4.4 0.3 2.3 15.5 4 20 54 26.1 
LT 6.1 2.9 0.4 0.7 2.5 20 19 28 22.6 
LV 7.8 4.1 0.1 0.2 0.8 13 20 32 21.8 
SK 8.0 4.0 0.4 1.0 8.2 9 12 38 19.5 
HR 6.2 2.9 0.9 2.4 7.7 13 17 22 17.4 
RO 5.5 2.6 1.2 2.1 9.5 12 11 20 14.1 
BY 6.8 3.0 0.0 0.0 0.9 2 3 33 12.6 
RS 5.1 2.5 1.4 1.9 6.9 14 10 14 12.3 
BG 6.0 3.0 0.2 0.4 1.8 7 7 12 8.7 
BA 2.9 1.2 0.0 0.1 0.4 2 5 8 5.0 
 
 
e-Figure 1.  Plot of the percentage disease burden from cancer in 2012 (in DALYs) compared 
with the wealth of EEU countries (2011, thousand US dollars, per head).  Country codes in 
Table 1. 
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e-Figure 2.  Burden of different cancers in three groups of EEU countries, 2010.  BALK = five 
Balkan countries; CIS = 12 members of the Commonwealth of Independent States; EU MS = 
11 European Union Member States.  For site codes, see Table 2. 
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Figure 3.  Relationship between cancer research papers in 2007-16 and GDP in 2011 for EEU 
countries.  CIS countries marked red; EU Member States marked blue; Baltic states marked 
green.  Grey lines above and below black trend-line show outputs x 10 and x 0.1.  Country 
codes in Table 1. 
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Figure 4.  Extent of international collaboration for 16 leading EEU countries in cancer research, 
2007-16.  Countries ranked by numbers of papers; blue bars: EU MS; red bars: CIS countries; 
green bars: Balkan countries.  Fractional country counts; for codes see Table 1. 
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e-Figure 5.  Extent of international collaboration for the 16 leading countries in two five-year 
periods.  Country codes as in Table 1. 
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Figure 6.  Scatter plot showing relationship between relative burden from cancer in 2012 
(abscissa) and percentage of biomedical research papers that are on cancer, 2007-16, for 28 
EEU countries (Kosovo not shown).  EU Member States: blue squares; CIS states: red squares; 
Balkan states: green squares.  For country codes, see Table 1.  Dashed line shows where 
research outputs are only half of percentages corresponding to burden. 
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e-Figure 7.  The amount of research from the EEU countries, 2007-16, as a function of the 
disease burden from different cancers, 2010.  Site codes in Table 2.  Diagonal lines show 
equivalent percentages, and ones that are x 2 or x 0.5 of the relevant burden. 
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Figure 8.  Partition of EEU cancer research papers by domain, 2007-16.  For codes, see Table 
2. 
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e-Figure 9.  Citation scores of EEU cancer papers on different sites.  For codes, see Table 2. 
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e-Figure 10.  Citation scores of EEU cancer papers in different research domains.  For codes, 
see Table 2.  CLIN TR = clinical trials 
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e-Figure 11.  The presence of scientists with one or more of over 2400 Russian names on 
papers from 1977-2016 in Russia (top graph) and in other countries (bottom graph; note 
different scale). 
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Figure Legends 
e-Figure 1.  Plot of the percentage disease burden from cancer in 2012 (in DALYs) compared 
with the wealth of EEU countries (2011, thousand US dollars, per head).  Country codes in 
Table 1. 
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Balkan countries; CIS = 12 members of the Commonwealth of Independent States; EU MS = 
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codes in Table 1. 
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